8-K filed Jul 30, 2026 at 06:53 ET
Labcorp reported Q2 2026 revenue of $3.73B (up 5.8% YoY) and adjusted EPS of $4.99, beating consensus of $4.77 by 4.6%. The company raised full-year 2026 adjusted EPS guidance to $18.10-$18.55 (up $0.30 at midpoint) and increased its share repurchase authorization by $1.0B to $1.4B. Strong operating margin expansion (adjusted operating margin +70bps to 15.8%) and double-digit adjusted EPS growth (+14.9% YoY) drove the beat, with both Diagnostics and Biopharma segments contributing to the upside.